FDA Approval Summary: Vorasidenib for <i>IDH</i> -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery
Michael I. Barbato(United States Food and Drug Administration), Nicole Drezner(Center for Drug Evaluation and Research), Amy Barone(United States Food and Drug Administration), Jianghong Fan(United States Food and Drug Administration), Sarah E. Dorff(United States Food and Drug Administration), Suryatheja Ananthula(University of Mississippi Medical Center), Barbara Scepura(Center for Drug Evaluation and Research), A. K. Sinha(United States Food and Drug Administration), Shan Pradhan(United States Food and Drug Administration), Maritsa Stephenson(United States Food and Drug Administration), Xiaoxue Li(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Hong Zhao(Center for Drug Evaluation and Research), Stephanie Aungst(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Erin Larkins(United States Food and Drug Administration), Claudia P. Miller(Center for Drug Evaluation and Research), Vishal Bhatnagar(United States Food and Drug Administration), Ye Xiong(United States Food and Drug Administration), Youwei Bi(Center for Drug Evaluation and Research), Nam Atiqur Rahman(United States Food and Drug Administration), Haleh Saber(United States Food and Drug Administration), Yuching Yang(United States Food and Drug Administration)
Cited by 9
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k